Genomics BioSci & Tech. Co.,Ltd. (TPEX:4195)
Taiwan
· Delayed Price · Currency is TWD 18.55
-0.15 (-0.80%)
Jul 11, 2025, 1:54 PM CST
Genomics BioSci & Tech. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 482.75 | 396.14 | 419 | 389.97 | 443.18 | Upgrade
| |
Revenue Growth (YoY) | 21.86% | -5.46% | 7.45% | -12.01% | 3.63% | Upgrade
|
Cost of Revenue | 360.4 | 276.23 | 282.99 | 280.04 | 288.16 | Upgrade
|
Gross Profit | 122.36 | 119.91 | 136.01 | 109.92 | 155.01 | Upgrade
|
Selling, General & Admin | 172.71 | 148.47 | 131.79 | 121.69 | 121.8 | Upgrade
|
Research & Development | 88.5 | 56.43 | 35.88 | 17.47 | 22.56 | Upgrade
|
Operating Expenses | 262.65 | 201.81 | 169.53 | 138.58 | 148.42 | Upgrade
|
Operating Income | -140.29 | -81.9 | -33.52 | -28.66 | 6.6 | Upgrade
|
Interest Expense | -7.74 | -4.74 | -1.98 | -1.67 | -1 | Upgrade
|
Interest & Investment Income | 2.37 | 2.09 | 0.35 | 0.27 | 1.17 | Upgrade
|
Earnings From Equity Investments | -52.72 | -19.56 | -18.88 | -13.46 | 2.89 | Upgrade
|
Currency Exchange Gain (Loss) | 0.43 | 0.86 | 0.72 | -1.31 | -2.44 | Upgrade
|
Other Non Operating Income (Expenses) | 12.08 | 0.58 | 0.8 | 1.05 | 0.69 | Upgrade
|
EBT Excluding Unusual Items | -185.87 | -102.67 | -52.5 | -43.78 | 7.91 | Upgrade
|
Gain (Loss) on Sale of Investments | -47.06 | -65.29 | 124.76 | -9.31 | -6.98 | Upgrade
|
Gain (Loss) on Sale of Assets | -1.06 | - | - | 65.18 | -4.04 | Upgrade
|
Asset Writedown | -1.36 | - | - | - | - | Upgrade
|
Other Unusual Items | 0 | 0.02 | - | 0.01 | 0 | Upgrade
|
Pretax Income | -235.35 | -167.94 | 72.26 | 12.09 | -3.1 | Upgrade
|
Income Tax Expense | - | 0.13 | 0.66 | - | -1.65 | Upgrade
|
Earnings From Continuing Operations | -235.35 | -168.07 | 71.6 | 12.09 | -1.45 | Upgrade
|
Net Income to Company | -235.35 | -168.07 | 71.6 | 12.09 | -1.45 | Upgrade
|
Minority Interest in Earnings | 12.25 | - | - | 6.65 | 2.07 | Upgrade
|
Net Income | -223.1 | -168.07 | 71.6 | 18.74 | 0.62 | Upgrade
|
Net Income to Common | -223.1 | -168.07 | 71.6 | 18.74 | 0.62 | Upgrade
|
Net Income Growth | - | - | 282.09% | 2927.14% | -99.27% | Upgrade
|
Shares Outstanding (Basic) | 72 | 71 | 63 | 60 | 60 | Upgrade
|
Shares Outstanding (Diluted) | 72 | 71 | 64 | 60 | 60 | Upgrade
|
Shares Change (YoY) | 1.89% | 11.87% | 5.12% | 0.23% | -0.47% | Upgrade
|
EPS (Basic) | -3.08 | -2.36 | 1.13 | 0.31 | 0.01 | Upgrade
|
EPS (Diluted) | -3.08 | -2.36 | 1.13 | 0.31 | 0.01 | Upgrade
|
EPS Growth | - | - | 267.48% | 3103.13% | -99.31% | Upgrade
|
Free Cash Flow | -305.39 | -246.28 | -115.21 | -121.35 | -61.53 | Upgrade
|
Free Cash Flow Per Share | -4.21 | -3.46 | -1.81 | -2.01 | -1.02 | Upgrade
|
Dividend Per Share | - | - | 0.098 | - | - | Upgrade
|
Gross Margin | 25.35% | 30.27% | 32.46% | 28.19% | 34.98% | Upgrade
|
Operating Margin | -29.06% | -20.67% | -8.00% | -7.35% | 1.49% | Upgrade
|
Profit Margin | -46.21% | -42.43% | 17.09% | 4.81% | 0.14% | Upgrade
|
Free Cash Flow Margin | -63.26% | -62.17% | -27.50% | -31.12% | -13.88% | Upgrade
|
EBITDA | -85.84 | -49.01 | -5.41 | 0.81 | 37.72 | Upgrade
|
EBITDA Margin | -17.78% | -12.37% | -1.29% | 0.21% | 8.51% | Upgrade
|
D&A For EBITDA | 54.45 | 32.89 | 28.1 | 29.47 | 31.12 | Upgrade
|
EBIT | -140.29 | -81.9 | -33.52 | -28.66 | 6.6 | Upgrade
|
EBIT Margin | -29.06% | -20.67% | -8.00% | -7.35% | 1.49% | Upgrade
|
Effective Tax Rate | - | - | 0.92% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.